ダイアミドの新興薬剤に関する洞察と市場予測：2032年

ダイアミドは、1型糖尿病を引き起こすインスリン産生β細胞の破壊を阻止することを目的とした自己免疫性糖尿病ワクチンです。ワクチンの有効成分はGAD65（グルタミン酸デカルボキシラーゼ-65）で、膵臓のβ細胞に自然に存在する酵素であり、β細胞が正常に働き、インスリンを産生し続けるのを助けます。ほとんどの1型糖尿病患者は、この酵素を標的とするGAD自己抗体を持っており、免疫系がインスリンを作る細胞を攻撃し、インスリン産生を停止させてしまいます。ダイアミド社のワクチンは、この破壊的プロセスを阻止するためにGAD65酵素を補充します。β細胞がインスリンを作り続けるのを助けることで、1型糖尿病の発症を阻止したり遅らせたりすることができます。

今後数年間で、1型糖尿病の市場シナリオは、世界中の広範な研究と医療支出の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、ダイアミドの優位性に影響を与える可能性のある機会を模索しています。1型糖尿病に対する他の新興製品もダイアミドと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるダイアミド市場について調査し、市場の概要とともに、2026年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 1型糖尿病に対するダイアミドの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 ダイアミド市場評価

• 1型糖尿病に対するダイヤミドの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国における1型糖尿病に対するダイヤミドの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Diamyd, Clinical Trial Description, 2023
• Table 2: Diamyd, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Diamyd Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Diamyd Market Size in the US, in USD million (2019-2032)
• Table 7: Diamyd Market Size in Germany, in USD million (2019-2032)
• Table 8: Diamyd Market Size in France, in USD million (2019-2032)
• Table 9: Diamyd Market Size in Italy, in USD million (2019-2032)
• Table 10: Diamyd Market Size in Spain, in USD million (2019-2032)
• Table 11: Diamyd Market Size in the UK, in USD million (2019-2032)
• Table 12: Diamyd Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Diamyd Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Diamyd Market Size in the United States, USD million (2019-2032)
• Figure 3: Diamyd Market Size in Germany, USD million (2019-2032)
• Figure 4: Diamyd Market Size in France, USD million (2019-2032)
• Figure 5: Diamyd Market Size in Italy, USD million (2019-2032)
• Figure 6: Diamyd Market Size in Spain, USD million (2019-2032)
• Figure 7: Diamyd Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Diamyd Market Size in Japan, USD million (2019-2032)

“"Diamyd Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about diamyd for type 1 diabetes mellitus in the seven major markets. A detailed picture of the diamyd for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the diamyd for type 1 diabetes mellitus. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the diamyd market forecast analysis for type 1 diabetes mellitus in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in type 1 diabetes mellitus.

Drug Summary:

Diamyd is an autoimmune diabetes vaccine that aims to stop the destruction of insulin-producing beta cells that lead to type 1 diabetes. The active ingredient in the vaccine is GAD65 (glutamic acid decarboxylase-65), an enzyme that occurs naturally in the pancreatic beta cells that helps them work properly and continue producing insulin. Most people with type 1 diabetes have GAD autoantibodies that target this enzyme, leading the immune system to attack the cells that make insulin, shutting off insulin production. Diamyd's vaccine supplements the GAD65 enzyme to stop this destructive process. It could thwart or delay the onset of type 1 diabetes by helping the beta cells continue to produce insulin.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the diamyd description, mechanism of action, dosage and administration, research and development activities in type 1 diabetes mellitus.
• Elaborated details on diamyd regulatory milestones and other development activities have been provided in this report.
• The report also highlights the diamyd research and development activities in type 1 diabetes mellitus across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around diamyd.
• The report contains forecasted sales of diamyd for type 1 diabetes mellitus till 2032.
• Comprehensive coverage of the late-stage emerging therapies for type 1 diabetes mellitus.
• The report also features the SWOT analysis with analyst views for diamyd in type 1 diabetes mellitus.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Diamyd Analytical Perspective by DelveInsight

In-depth Diamyd Market Assessment

This report provides a detailed market assessment of diamyd for type 1 diabetes mellitus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

Diamyd Clinical Assessment

The report provides the clinical trials information of diamyd for type 1 diabetes mellitus covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for type 1 diabetes mellitus is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence diamyd dominance.
• Other emerging products for type 1 diabetes mellitus are expected to give tough market competition to diamyd and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of diamyd in type 1 diabetes mellitus.
• Our in-depth analysis of the forecasted sales data of diamyd from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the diamyd in type 1 diabetes mellitus.

Key Questions:

• What is the product type, route of administration and mechanism of action of diamyd?
• What is the clinical trial status of the study related to diamyd in type 1 diabetes mellitus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the diamyd development?
• What are the key designations that have been granted to diamyd for type 1 diabetes mellitus?
• What is the forecasted market scenario of diamyd for type 1 diabetes mellitus?
• What are the forecasted sales of diamyd in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to diamyd for type 1 diabetes mellitus?
• Which are the late-stage emerging therapies under development for the treatment of type 1 diabetes mellitus?

Table of Contents

1. Report Introduction

2. Diamyd Overview in type 1 diabetes mellitus

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Diamyd Market Assessment

• 5.1. Market Outlook of Diamyd in type 1 diabetes mellitus
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Diamyd in the 7MM for type 1 diabetes mellitus
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Diamyd in the United States for type 1 diabetes mellitus
  • 5.3.2. Market Size of Diamyd in Germany for type 1 diabetes mellitus
  • 5.3.3. Market Size of Diamyd in France for type 1 diabetes mellitus
  • 5.3.4. Market Size of Diamyd in Italy for type 1 diabetes mellitus
  • 5.3.5. Market Size of Diamyd in Spain for type 1 diabetes mellitus
  • 5.3.6. Market Size of Diamyd in the United Kingdom for type 1 diabetes mellitus
  • 5.3.7. Market Size of Diamyd in Japan for type 1 diabetes mellitus

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options